Saliva Diagnostic Systems Announces New CEO

Saliva Diagnostic Systems Announces New CEO
Steve Peltzman to Lead Next Phase of Company's Growth 


NEW YORK, April 12  /PRNewswire-FirstCall/ -- Saliva Diagnostics Systems, Inc.
(OTC:SVAD) (BULLETIN BOARD: SVAD)  is pleased to announce the appointment of
Mr. Steve Peltzman as CEO, effective March 25, 2005. Mr. Peltzman has been
working closely with the Company as a consultant for the last 6 months. Mr.
Peltzman has more than thirty years of business experience in technology-based,
health-care companies. In 1984, he helped start and served as President and CEO
of Applied bioTechnology, Inc. whose cancer business was sold to OSI
Pharmaceuticals in 1991, when he became Chief Operating Officer of the
consolidated entity; from 1994 through 1997 he served as President and COO of
OSIP and remained on its Board of Directors through 1999. From 1980 to 1984,
Mr. Peltzman held senior executive positions with Millipore and for ten years
preceding that was with Corning Glass Works' Medical diagnostic and device
businesses. During the past several years he has been active in several small
health care and technology start-ups as their interim CEO or COO or in an
advisory capacity to their Boards of Directors.

Mr. Peltzman stated his reasons for joining the firm: "SDS is poised to become
a key player in the embryonic, point-of-care, rapid testing market, targeting
sexually transmitted and other important infectious diseases. The need to
accurately, inexpensively, safely and quickly identify millions of infected
individuals throughout the globe is a critical first step in cost effectively
dealing with the devastating consequences of HIV, hepatitis and a myriad of
other pathogens. SDS's proprietary format for rapid testing appears to be an
ideal fit to commercially solve certain of these problems that seriously impact
our public health systems and world economies."

About Saliva Diagnostic Systems (SDS)

Saliva Diagnostic Systems manufactures and markets a patented rapid point of
care testing device for infectious diseases, as well as oral fluid specimen
collection devices using a patented volume adequacy indicator for drugs of
abuse testing and other clinical uses. These products are sold in the United
States as well as internationally to various distributors for use in clinical
laboratories, hospitals, clinics, community-based organizations and other
public health organizations. Please visit our website at http://www.salv.com/

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts are forward-looking
statements within the meaning of the Securities Act of 1933, as amended. Those
statements include statements regarding the intent, belief or current
expectations of the Company and its management. Such statements reflect
management's current views, are based on certain assumptions and involve risks
and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited to,
the Company's ability to obtain additional financing and the demand for the
Company's products. The Company undertakes no obligation to publicly update
these forward-looking statements to reflect events or circumstances that occur
after the date hereof or to reflect any change in the Company's expectations
with regard to these forward-looking statements or the occurrence of
unanticipated events. Factors that may impact the Company's success are more
fully disclosed in the Company's most recent public filings with the U.S.
Securities and Exchange Commission ("SEC"). 

DATASOURCE: Saliva Diagnostics Systems, Inc.



CONTACT:  Investor Relations, Saliva Diagnostics Systems, Inc.,

[phone]



Web site:  http://www.salv.com/ 

Copyright